Related Experiment Video
Updated: Jun 14, 2026
08:11
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
23.1K
Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review
Anton Raemy1, Laurence May1, Nathalie Sala2
1Department of Maxillofacial Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Cancers
|June 27, 2024
Summary
Anti-MAPK targeted therapy shows promise for treating ameloblastoma, a challenging odontogenic tumor. This approach offers a less invasive, effective alternative to surgery, with most patients experiencing positive responses and mild side effects.
Area of Science:
- Oncology
- Oral and Maxillofacial Surgery
- Pharmacology
Background:
- Ameloblastoma is a benign but aggressive odontogenic tumor.
- It is characterized by high recurrence rates and significant morbidity associated with radical surgical interventions.
- Current treatment paradigms may be improved by targeted therapies.
Purpose of the Study:
- To evaluate the safety and efficacy of anti-MAPK targeted therapy for ameloblastoma.
- To review existing literature on MAPK inhibitor therapies in ameloblastoma patients.
Main Methods:
- Systematic review registered in PROSPERO, adhering to PRISMA guidelines.
- Searched multiple databases up to December 2023.
- Included 13 studies encompassing 23 patients treated with MAPK inhibitors.
Main Results:
- Nearly all patients demonstrated a positive treatment response to anti-MAPK therapy.
- Four patients achieved complete radiological remission.
- Substantial reductions in tumor size were observed in primary, recurrent, and metastatic ameloblastoma.
- Reported side effects were predominantly mild to moderate.
Conclusions:
- Anti-MAPK therapy represents a significant advancement over traditional surgical treatments for ameloblastoma.
- This targeted approach offers a less invasive and effective alternative, potentially improving patient quality of life and clinical outcomes.
- Further research into molecular-targeted therapies for ameloblastoma is warranted.
